CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 100 enrolled
Drug / intervention
Regadenosondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00837369
NCT00837369Phase 1Completed
CompareCT.gov

Regadenoson Real Time Perfusion Imaging Trial

University of Nebraska·interventional·Posted Feb 5, 2009·Updated Dec 27, 2024

In Brief

A Phase 1 clinical trial evaluating Regadenoson for Coronary Artery Disease and Myocardial Perfusion Abnormalities. Completed, enrolled 100 participants across 2 sites.

Detailed Summary

To exam the feasibility and accuracy of Regadenoson real time perfusion (RTPE) Imaging during vasodilator stress with Regadenoson for detection of significant coronary artery disease (CAD) in patients scheduled to undergo coronary angiography.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease, Myocardial Perfusion Abnormalities
CountriesUnited States
CollaboratorsMayo Clinic, Astellas Pharma Inc

Timeline

Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 5, 2009
Enrollment StartApr 7, 2009
Primary CompletionMar 1, 2011
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 17.4 years ago

Interventions

Regadenosondrug

400ug IV bolus injection, single dosage